HRM method for identification of TP53 exon 5 and 8 mutations in human prostate cancer patients

Basit Öğe Kaydı
dc.authorid0000-0002-0211-3450
dc.contributor.authorÖzmerdiven, Çağdaş Gökhun
dc.contributor.authorDirican, Ebubekir
dc.contributor.authorAyan, Semih
dc.contributor.authorTatar, Zeynep
dc.contributor.authorÇakır, Sami
dc.contributor.authorGüler, Yavuz
dc.contributor.authorKaradağ, Abdullah
dc.contributor.authorSoydaş, Tuğba
dc.contributor.authorKarabulut Uzunçakmak, Sevgi
dc.contributor.authorAru, Melek
dc.contributor.authorKanigur, Gönül
dc.contributor.authorİlvan, Ahmet
dc.date.accessioned2022-05-27T11:52:51Z
dc.date.available2022-05-27T11:52:51Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı
dc.description.abstractBackground: The purpose of the present study was to perform a high-resolution melting (HRM) analysis to discover mutations in gene exons 5-8 of tumor protein p53 (TP53), as well as the relationships of these mutations to clinical parameters in prostate cancer (PC).& nbsp;Methods: Genomic DNA was extracted from 50 formalin-fixed paraffin-embedded (FFPE) tissues with PC. Mutations in exons 5 and 8 of TP53 were analyzed using the HRM method. Sanger sequencing was used to describe mutations.& nbsp;Results: According to the HRM analysis results, 21 (42%) PC samples had different normalized and shifted melting curves from other samples. Mutations in TP53 exons 5 and8 were observed in 12 (24%) patients by the Sanger method. The detection sensitivity of the HRM method in exon 5 and exon 8 mutations was 66.7% and 50%, respectively. PSA levels of PC patients with TP53 mutation were found to be lower than that of patients with no mutation (p = 0.8270). However, we did not find any correlations between TP53 mutations and clinical parameters (p > 0.05).& nbsp;Conclusions: HRM analysis is a simple, rapid, and efficient mutation-scanning method for known/unknown mutations in TP53 exons 5and8, as well as an attractive method for detection of mutations and their analysis in FFPE tissues. Additional studies with larger patient populations are warranted to confirm the correlation between the TP53 mutations and PC risk.
dc.description.sponsorshipResearch Foundation of Istanbul Aydin University (BAP)en_US
dc.identifier.citationÖzmerdiven, Ç. G., Dirican, E., Ayan, S., Tatar, Z., Çakır, S., Güler, Y. ... İlvan, A. (2022). HRM method for identification of TP53 exon 5 and 8 mutations in human prostate cancer patients. Meta Gene, 31. https://doi.org/10.1016/j.mgene.2022.101020
dc.identifier.doi10.1016/j.mgene.2022.101020
dc.identifier.issn2214-5400
dc.identifier.scopus2-s2.0-85149372538
dc.identifier.scopusqualityQ4
dc.identifier.urihttps://doi.org/10.1016/j.mgene.2022.101020
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9478
dc.identifier.volume31
dc.identifier.wos000792756700012en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorÇakır, Sami
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofMeta Geneen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectHRM
dc.subjectProstate Cancer
dc.subjectSanger
dc.subjectFFPE
dc.subjectTP53
dc.subjectPCR
dc.titleHRM method for identification of TP53 exon 5 and 8 mutations in human prostate cancer patients
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Cakir-Sami-2022.pdf
Boyut:
691.23 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu